Satipharm begins clinical trial of CBD capsules for treating menopause
Category: #health  By Saipriya Iyer  Date: 2020-02-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

Satipharm begins clinical trial of CBD capsules for treating menopause

Cannabis was prior considered to possess various medicinal benefits for treating diseases. However, after years of restriction, the scientific community is finally exploring the medical avenues of CBD by conducting advanced clinical trials and creating new formulations.

Recently, Satipharm Ltd., a wellness and health firm, took a pioneering step towards this direction by initiating a clinical research on CBD capsules for offering patients the needed relief from menopause symptoms.

After the fruitful conclusion of Phase II clinical study indicating that Satipharm CBD capsules minimized seizures in kids with an average 73% of treatment-resistant epilepsy, the company is reportedly shifting its focus towards menopause and perimenopause.

Reports cite that using these advanced CBD capsules along with Gelpell® delivery technology, which is developed under Good Manufacturing Practice ("GMP"), would allow Satipharm to validate its patented CBD formulation as it offers substantial relief from physiological-based symptoms.

Speaking on the move, Jonathan Hartshorn, CEO, Satipharm, said that delivering clinical proof to its users, upon which they can rely on to take their healthcare decisions, has been a key objective for Satipharm.

After the success of its Phase II clinical study in epilepsy, the company has been constantly exploring new avenues of research to progress its understanding of CBD. It is observing numerous evidence that bolsters the benefits of CBD for women looking for relief from menopausal and perimenopausal symptoms.

However, the Food Standards Agency (FSA) has a contradicting opinion over the use of CBD by expecting women. The regulator has warned breastfeeding mothers and pregnant women to restrict their CBD medications to no more than 70mg a day.

As for CBD businesses, the regulator warned that their products could hit the bins if they failed to clarify the contents and safety of their items by the end of March 2021. Meanwhile, manufacturers are requested to register themselves with the FSA for “novel food authorization”. This grade would help the public to gain perspective about the safety profile of CBD products.

Source Credit: https://finance.yahoo.com/news/satipharm-initiates-clinical-research-cbd-080000122.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Regeneron begins late-stage trial of its coronavirus antibody cocktail
Regeneron begins late-stage trial of its coronavirus antibody cocktail
By Saipriya Iyer

Renowned American biopharmaceutical company, Regeneron Pharmaceuticals, has reportedly announced that it has started late-stage clinical trials of its proprietary antibody cocktail to assess its effectiveness in treati...

China completes 2 launches in 3-day span with Gaofen & Shiyan-6
China completes 2 launches in 3-day span with Gaofen & Shiyan-6
By Saipriya Iyer

China has recently launched its classified Shiyan-6 (02) satellite, following the launch of Gaofen, which is a ‘multimode’ Earth observation satellite, into orbit 2 days earlier. These two launches will mar...

Tetra Pak announces target to reach net-zero GHG emissions by 2030
Tetra Pak announces target to reach net-zero GHG emissions by 2030
By Saipriya Iyer

Tetra Pak, a food processing and packaging solutions provider, has recently announced its target to reach net-zero GHG (greenhouse gas) emissions in its operations by 2030.

The targ...